Research and Development

Showing 15 posts of 9573 posts found.

shire_image_4

Shire gets extended market authorization in Europe for drug to treat children with a rare gastrointestinal condition

July 7, 2016 Research and Development, Sales and Marketing European Commission, Revestive, Shire, market authorisation, short bowel syndrome

UK drugmaker Shire (LSE: SHP) said the European Commission has granted extension of Market Authorization for Revestive (teduglutide) to treat …

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016 Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …
takeda_world

Takeda says its cancer drug Adcetris gets European backing in for hodgkin lymphoma

July 6, 2016 Research and Development European Commission, Takeda, drug trial, lymphoma

Takeda Pharmaceutical (TSE: 4502) said the European Commission has extended the marketing authorization for its Adcetris (brentuximab vedotin) to treat …
clinical_trial_3

Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer

July 6, 2016 Research and Development Merck, Pfizer, avelumab

Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …

Wickham Laboratories Announces New In Vitro Pyrogenicity Testing Method

July 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test, for …
az_logo

AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate

July 6, 2016 Research and Development, Sales and Marketing AstraZeneca, Heptares

AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …

Sanofi says to co-develop Zika vaccine with US government

July 6, 2016 Research and Development, Sales and Marketing Sanofi, US government, Vaccine, Zika virus, drug development, research

French drugmaker Sanofi (Euronext: SAN) said it will co-develop a Zika vaccine candidate with the US government.  No financial details …

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million

July 6, 2016 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant

Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …

Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal

July 6, 2016 Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer

Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …

UCB scores Japanese approval for seizure therapy, Vimpat

July 5, 2016 Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
eisa0005

Eisai launches cancer drug Lenvatinib in Mexico

July 4, 2016 Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch

Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …
allergan

Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators

July 4, 2016 Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial

Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …
amgen_hq

Amgen says its blood cancer drug gets European backing for extended indication

July 4, 2016 Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial

Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …
The Gateway to Local Adoption Series

Latest content